Background: Patients with BRCA-associated ovarian cancer (OC) have a survival advantage over those with sporadic OC. To further explore this, we examined the impact of prognostic factors on disease-free survival (DFS) and overall survival (OS) in patients with known BRCA mutation status.
introduction Almost 22 000 new cases of epithelial ovarian cancer (OC) are expected in the United States in 2009 [1] . Between 8% and 13% of these will be due to a hereditary susceptibility [2] [3] [4] , with mutations in BRCA1 or BRCA2 accounting for the majority. BRCA-associated cancers are typically of serous histology, moderate to high grade, advanced stage, and diagnosed at a younger age than sporadic OCs [5] .
Rubin et al. [6] first reported in 1996 that BRCA-associated OC had a better prognosis than sporadic OC. Close to a dozen studies have since investigated this finding but interpretation of results has been limited by inadequate adjustment for known prognostic factors, retrospective design, short follow-up, and nonuniform treatment of cases and controls [7] . A large study of 779 Israeli women reported, with a median follow-up of 6.2 years, that BRCA-associated OC was associated with improved survival compared with sporadic disease (median survival, 55.7 versus 37.9 months, P = 0.002) [8] . A previous study reported a similar survival advantage for BRCA(+) OC and additionally analyzed survival by BRCA mutation type [5] . In this series of 88 BRCA-associated cancers (67 BRCA1 and 21 BRCA2) and 101 sporadic cancers, median survival in BRCA1(+) patients was significantly longer than sporadic cases (P = 0.008), and there was a nonsignificant trend toward better survival for BRCA2-associated cases (P = 0.09). The authors postulated that this better prognosis was due to either a different biology or a better response to treatment.
Preclinical data suggest that BRCA-associated OC is particularly sensitive to platinum-based chemotherapy [9, 10] , and clinical data appear to support this hypothesis. Tan et al. [11] reported significantly greater response to first-, second-, and third-line platinum-based chemotherapy for BRCAassociated OC compared with sporadic disease, and upon relapse, BRCA-associated OC appears to progress more slowly. To examine if the improved outcome of BRCA-associated OC is due to enhanced chemosensitivity or to other biologic differences, we investigated whether known prognostic factors, including platinum sensitivity, explained any observed differences in survival, between BRCA(+) and BRCA(2) patients.
materials and methods design
All patients initiating primary chemotherapy at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1 December 1996 and 30 September 2006 for surgical stage III or IV epithelial OC were considered. This cohort of patients was then cross referenced with a database of patients who underwent genetic testing for BRCA mutations in the context of one of two Institutional Review Board-approved prospective follow-up studies being conducted by the Clinical Genetics Service at MSKCC investigating the clinical significance of germline BRCA mutations [12] . For patients whose four grandparents were all of Ashkenazi Jewish heritage, germline DNA was screened for the three Ashkenazi founder mutations (BRCA1 · 185delAG, BRCA1 · 5382insC, and BRCA2 · 6174delT). If these were wild type and there was a strong family history of ovarian or early-onset breast cancer, sequencing of the coding and flanking intronic regions was carried out by Myriad Genetics (Salt Lake City, UT). For participants who were not of exclusive Ashkenazi ancestry, sequencing of BRCA1 and BRCA2 was carried out. For the purposes of this study, five individuals with variants of uncertain significance were recorded as BRCA mutation negative. Testing for structural rearrangements was not carried out during the study time frame.
MSKCC gynecologic medical oncology records were reviewed for all patients who received treatment at MSKCC and also had BRCA mutation testing results available. Patients with pure mucinous OC were excluded as mucinous OC is rarely associated with BRCA mutations [5, 13] . The remaining patients with nonmucinous epithelial OC comprised our final study cohort. Medical records were then reviewed and data were collected regarding age, diagnosis date, debulking status, stage, pathology, primary site, Ca125 at diagnosis, type and duration of chemotherapy, date of completion of platinum, Ca 125 nadir, response to chemotherapy, recurrence date, secondary cytoreduction, last follow-up if alive, disease status at last follow-up, and date of death if dead.
Surgical stage and histological cell type were categorized according to the International Federation of Gynecology and Obstetrics and World Health Organization standards. The date of diagnosis was defined as the date of initial surgery, which was characterized at the time of operation as optimal or suboptimal. Optimal debulking was described as residual disease <1 cm and suboptimal as residual disease ‡1 cm. Response to chemotherapy was determined by computed tomography (CT) scan upon completion of treatment. Recurrence was diagnosed by CT scan or rise in Ca125 or both. Recurrence by Ca125 was defined as doubling of the upper limit of normal if the nadir was in the normal range (0-35 U/ml) or doubling from the nadir if it was outside of the normal range [14] . Platinum-resistant disease was defined by recurrence at £6 months after completion of treatment. Disease-free survival (DFS) was calculated from time of diagnosis to time of recurrence and overall survival (OS) from time of diagnosis to time of death. Platinum-free interval (PFI) was calculated from date of last platinum treatment to date of recurrence.
biostatistics
The primary objective of this study was to compare DFS and OS of patients with BRCA-associated, advanced stage, nonmucinous epithelial OC with DFS and OS in women with sporadic OC after adjusting for known clinical prognostic factors. DFS and OS were calculated using the Kaplan-Meier method and compared using the log-rank test, with hazard ratios and 95% confidence intervals (CIs) calculated using a Cox regression model with a single covariate. Potential prognostic variables analyzed in the univariate analysis were mutation status, age at diagnosis (<60 or ‡60 years), debulking status (optimal or suboptimal), primary platinum sensitivity (sensitive or resistant), Ca125 nadir (<20 or ‡20 U/ml), use of consolidation treatment (yes or no), and histology (serous or nonserous)]. Variables significant at an a = 0.10 were then incorporated into a multivariate Cox proportional hazards model to identify independent prognostic factors and estimate the associations between these covariates and OS [15, 16] .
To examine if BRCA mutation status was an independent predictor of survival in the second-line setting, similar univariate and multivariable analyses were carried out for the 78 patients who recurred after initial chemotherapy. For this analysis, survival was calculated from time of recurrence to time of last follow-up or death. Secondary cytoreduction (yes or no) was additionally incorporated as a potential prognostic variable in this analysis.
results
Eight hundred eight patients initiated primary chemotherapy through the Gynecologic Medical Oncology service at MSKCC for surgical stage III or IV epithelial OC between 1 December 1996 and 30 September 2006. One hundred ten of these patients (94 ovarian, 12 primary peritoneal, and 4 fallopian tube) had nonmucinous OC and known BRCA mutation status [36 patients were BRCA(+) and 74 BRCA (2)]. Of the 36 BRCA mutations (20 BRCA1 and 16 BRCA2), 23 were one of the Ashkenazi Jewish founder mutations. Clinical and pathological characteristics of BRCA(+) and BRCA(2) patients are detailed in Table 1 . BRCA(+) patients were slightly younger (mean 58.4 versus 60.1 years; P = 0.10) and less likely to be optimally debulked (53% versus 65%; P = 0.40). The majority of patients were stage III (92%) and had serous pathology (81%). The median Ca125 at diagnosis for BRCA(+) patients was 824 (range, 15-13 150) and for BRCA(2) patients was 556 (5-14 512). The median Ca125 nadir for both groups was 10. Thirty-one of 36 (86%) BRCA(+) and 60 of 74 (81%) BRCA(2) patients had platinum-sensitive disease (P = 0.60). After a median follow-up of 41 months, 24 (67%) BRCA(+) and 54 (73%) BRCA(2) patients had relapsed. Five (14%) BRCA(+) and 26 (35%) BRCA(2) patients are dead of disease. Median DFS was 24.0 months in the BRCA(2) patients and 26.9 months in the BRCA (+) patients (P = 0.30). Median OS in BRCA(2) patients was 67.8 months and was not yet reached in BRCA(+) patients (P = 0.02) (Figure 1) . On univariate analysis, presence of a BRCA mutation (P = 0.016), platinumsensitive disease (P < 0.001), and Ca125 nadir <20 (P = 0.044) were significantly associated with improved OS after first-line therapy. When incorporated into the multivariate model, OS independently correlated with both primary platinum sensitivity (HR = 0.15; 95% CI 0.06-0.34) and BRCA(+) mutation status (HR = 0.33; 95% CI 0.12-0.86) but not with Ca125 nadir <20 ( Table 2) .
After second-line therapy, presence of a BRCA mutation (P = 0.028), platinum-sensitive disease (following first-line therapy) (P = 0.005), and age <60 years (P = 0.017) were significantly associated with improved survival from time of recurrence on univariate analysis. Additionally, there was a suggestion that secondary cytoreduction (P = 0.089) was also associated with improved survival in the second-line setting, and this was included as a covariate in the multivariate analysis. On multivariate analysis, only BRCA(+) mutation status (HR = 0.36; 95% CI 0.14-0.93) and age ‡60 years (HR = 2.30; 95% CI 1.01-5.21) remained significantly associated with survival. There was, however, a suggestion that primary platinum sensitivity was also associated with improved survival in the second-line setting (HR = 0.47; 95% CI 0.22-1.03; P = 0.058).
discussion
In this study, we confirm the survival benefit associated with BRCA(+) OC in 110 patients with stage III or IV ovarian, primary peritoneal or fallopian tube cancer. Median survival for the BRCA(2) group was 67.8 months and not yet reached for the BRCA(+) group (P = 0.02). The survival of both groups compares favorably with historical controls, particularly considering that only 65% and 53% of patients were optimally debulked, respectively. The best reported median survival to date is from GOG172, a randomized phase III study that compared adjuvant intraperitoneal (i.p.) plus systemic chemotherapy with systemic treatment alone, for patients with optimally debulked ovarian or primary peritoneal cancer [17] . The BRCA status of participants was not available, but median survival was significantly greater in the i.p. therapy cohort (65.6 months), compared with patients who received systemic therapy alone (49.7 months; P = 0.03). Only eight patients in our study received postoperative i.p. chemotherapy [4 (12%) BRCA(+) and 4 (5%) BRCA (2)], and therefore, the reported survival was achieved predominantly with surgery plus systemic chemotherapy. One explanation for the better-than-expected survival in this cohort is the timing of BRCA mutation testing, which occurred at a median of 11.1 months following diagnosis. Given that testing was not carried out at diagnosis, we may have preferentially selected patients with good biology disease. However, this should not substantially impact the survival difference observed as the time interval between diagnosis and testing was similar for BRCA mutation carriers (9.4 months) and noncarriers (12.7 months). Our exclusion of mucinous cancers may also have contributed to the long median survival (exceeding 5 years in both groups).
In the present report, only primary platinum sensitivity and BRCA mutation status were independent predictors of OS on multivariate analysis. Stage, grade, age, histology, the presence of ascites, surgical debulking status, and PFI, however, have all been previously reported as predictive of outcome in epithelial OC with unknown BRCA mutation status [18] [19] [20] . Limited information, though, is available regarding the role of these factors in OCs characterized for BRCA mutations. A relationship between PFI and survival may be expected considering response correlates with survival across most tumor types, and in OC, response to first-line platinum 
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predicts response to second-line platinum. However, the results of our analysis, as well as the absence of an association between DFS and mutation status, strongly suggest that biologic differences beyond platinum sensitivity associated with loss of BRCA function may contribute to the improved survival seen in this and other studies.
Some other commonly reported prognostic factors, including age, were not predictive of survival after first-line treatment in this study. Younger patients typically present with better performance status. However, BRCA1-associated OCs also typically present 10 years earlier than sporadic OCs [5] , so it is possible that younger age may also be a surrogate for having a BRCA-associated cancer.
Optimal surgical debulking has consistently been associated with improved outcome in retrospective analyses [21, 22] but was not an independent predictor of survival in this study. The relationship between debulking status and other clinical parameters was illustrated in a multivariate analysis of 798 patients with International Federation of Obstetricians and Gynaecologists (FIGO) IIB-IV OC. Preoperative tumor load, FIGO stage, performance status, age, presence of peritoneal carcinomatosis, and surgical experience were all independently predictive of the chance of achieving a complete debulking [23] . Furthermore, tumor burden after debulking has previously been associated with response to chemotherapy [18] , which in turn is associated with survival. It is difficult to separate all potentially relevant clinical factors in a retrospective review, but debulking status may simply be a surrogate for tumor biology. Once the biology is defined by BRCA status, it is possible that extent of surgery no longer impacts on outcome.
The enhanced platinum sensitivity of BRCA-associated malignancies may be explained by the tumor's inability to repair double-stranded DNA breaks, and a new class of agents, poly-ADP-ribose polymerase-1 (PARP1) inhibitors, have recently been introduced into the clinical setting that capitalize on this unique biology. A number of phase I and II studies have reported the success of PARP inhibition in BRCA-associated malignancies and in triple-negative breast cancer, and phase III studies are underway [24] [25] [26] . However, recent data supporting greater platinum sensitivity in the first-, second-, and third-line for BRCA-associated OC compared with non-BRCA-associated disease [11] , suggest that clinical trials in BRCA-associated OC should include a platinum-based control arm, unless only proven platinum-refractory patients are included.
Further, as the present study suggests, platinum sensitivity may only partially explain the improved survival associated with BRCA mutations, and further biologic differences may exist between BRCA-associated and sporadic OC. One possibility is that BRCA-associated tumors elicit a greater immune response than sporadic tumors. Evidence in support of this hypothesis includes recent data suggesting that loss of BRCA1 function is associated with an increased likelihood of having intratumoural T cells [27] , which has previously been shown to correlate with improved progression-free survival and OS in OC [28] . This is a small study of only 36 BRCA(+) and 74 BRCA(2) patients. Interpretation of the results is limited by the small size; however, the findings are consistent with previous reports [11] . This supports the validity of our report and suggests that BRCA mutation status may be an important consideration in future OC clinical trial design. While all patients included in this study were enrolled on prospective clinical trials at MSKCC, most of the data were collected in a retrospective chart review. Even though data collection was carried out without knowledge of the mutation status of the patients, the potential bias of this approach must be acknowledged. A prospective cohort study would likely circumvent the referral bias that most likely explains the difference in age at presentation between BRCA carriers and noncarriers in this study. Younger patients are more commonly referred for genetic testing than older patients, and the median age of presentation in this study was younger than the average age of diagnosis in the population. With regard to mutation testing, false-negative BRCA results are possible due to limitations in genetic screening technologies. Commonly used mutation detection techniques are unable to detect intronic mutations and structural gene rearrangements [29] ; however, if present, these would bias toward the null and further strengthen our finding. Additionally, details of second-line systemic treatment were not included in our analysis. While all patients received upfront debulking followed by adjuvant platinum-based chemotherapy [77% received systemic carboplatin and paclitaxel (Paclitaxel)], treatment thereafter was very varied and included surgery, chemotherapy, hormonal therapy, and immunotherapy. A detailed analysis of response to different second-line therapies was therefore not feasible in this small cohort; however, even with this limitation, mutation status remained significant on multivariable analysis, again suggesting that BRCA-associated OC is a distinct biological entity with improved survival. The importance of debulking surgery being carried out at high volume centers has also been previously reported [23] . Not all patients were operated on at the same center and we can therefore not be certain of uniform surgical experience. Finally, our failure to identify debulking status as an independent prognostic factor may also be due to the small number of patients in this study. A larger study from our institution of 296 patients with unknown BRCA mutation status concluded that the amount of residual disease after debulking was significantly associated with response to platinum in a multivariable model that included age and stage [30] . Despite these limitations, our data suggest that BRCA status predicts OS, independent of primary platinum sensitivity. In summary, we confirm previous reports of improved survival associated with BRCA-associated OC. Our study supports preclinical and clinical data suggesting that BRCAdeficient tumors are more platinum sensitive and, importantly, also suggests that BRCA status is predictive of survival, independent of primary platinum sensitivity. It is possible that we have reached a plateau analyzing clinical predictive factors alone and need to incorporate molecular predictors into both clinical practice and trial design, as is being undertaken with KRAS in colorectal cancer [31] [32] [33] . Furthermore, it remains to be seen if somatic mutations and epigenetic alterations in BRCA are similarly predictive of improved outcome. Our findings should be considered hypothesis generating but warrant further investigation in a larger study. 
